Adding blinatumomab to chemotherapy reduces recurrence risk in standard-risk paediatric B-ALL
Tag: Tumour biomarkers
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
Immune-checkpoint inhibitors (ICIs) have improved clinical outcomes across several solid tumour types. Prominent efforts have focused on understand…
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
Circulating tumour DNA (ctDNA) can be released by cancer cells into biological fluids through apoptosis, necrosis or active release. In patients wi…
Chromothripsis in cancer
Chromothripsis is a mutational phenomenon in which a single catastrophic event generates extensive rearrangements of one or a few chromosomes. This…
Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection
Genomic analyses of cell-free DNA (cfDNA) in plasma are enabling noninvasive blood-based biomarker approaches to cancer detection and disease monit…
Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence
Despite advances in precision oncology, clinical decision-making still relies on limited variables and expert knowledge. To address this limitation…
Integrative single-cell and bulk transcriptomes analyses reveals heterogeneity of serine-glycine-one-carbon metabolism with distinct prognoses and therapeutic vulnerabilities in HNSCC
Metabolic heterogeneity plays a central role in sustaining uncontrolled cancer cell proliferation and shaping the tumor microenvironment (TME), whi…
Multiomic quantification of the KRAS mutation dosage improves the preoperative prediction of survival and recurrence in patients with pancreatic ductal adenocarcinoma
Most cancer mutation profiling studies are laboratory-based and lack direct clinical application. For clinical use, it is necessary to focus on key…